Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Extends Commitment to InforSense Technology

NEW YORK, Jan. 16 (GenomeWeb News) - AstraZeneca will extend its use of InforSense's informatics platform, InforSense said today.

 

InforSense, based in London, will build a new Open Discovery Workflow platform at AstraZeneca's research site in Molndal, Sweden, which will be accessed by researchers at several AstraZeneca sites.

 

AstraZeneca has been using InforSense technology since 2001.

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.